(Fixes dropped letter in headline)
BERLIN, March 22 (Reuters) - Shares in Alcon, the eye care business being spun-off by Novartis, are expected to start trading on April 9 on the Swiss Market and the New York Stock Exchange, Novartis said on Friday.
"Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange," Novartis said in a statement, adding that Alcon would enter the SMI, Switzerlands blue-chip stock index, on its first trading day.
Novartis added Alcon had secured debt financing of $3.5 billion, adding that Bank of America Merrill Lynch and UBS AG were advising Novartis on the transaction. (Reporting by Riham Alkousaa, Editing by Tassilo Hummel)